Phase III BRUIN CLL-314 Trial is Now Enrolling Patients with CLL, SLL
By Cecilia Brown, Jennifer Woyach, MD - Last Updated: June 9, 2023Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, speaks about the BRUIN CLL-314 study.
Advertisement
The phase III study will evaluate pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. It is currently enrolling patients.
Dr. Woyach and colleagues presented information about the study’s design and enrollment process during the 2023 American Society of Clinical Oncology Meeting.
Post Tags:ASCO2023
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.